There seems to be ever increasing evidence that a major effect of statins is protection of endothelial integrity and function and that the HDL and LDL effects may be secondary. Atromid-S was one of the first drugs that improved lipid assays but also increased mortality. Now we see more that are either ineffective or harmful.
Experimental Cholesterol Drug Does Not Cut Risk for Cardiovascular Events — Physician’s First Watch
Experimental Cholesterol Drug Does Not Cut Risk for Cardiovascular Events
By the Editors
Evacetrapib, an experimental cholesterol ester transfer protein inhibitor, raises HDL cholesterol and lowers LDL cholesterol — but does not reduce risk for cardiovascular events — according to an industry-funded, phase 3 trial in the New England Journal of Medicine.
Dr. Harlan Krumholz, editor-in-chief of NEJM Journal Watch Cardiology, offers his take on the findings at the link below.